Table 2 Basic characteristic table
Author\Year \Country | study design | Study period | ET cycle | Intervention group | Control group | Definition of RIF | Outcomes |
|---|---|---|---|---|---|---|---|
Kalem 2020 Turkey | RCT | 2016.3–2017.12 | Fresh cycle | Administered 30 mIU/ml of Leucotomy®(Filgrastim [G-CSF]; DEM Medical, Dong-A; South Korea) through slow infusion into the endometrial cavity using a soft embryo transfer catheter | 1 mL normal saline of infused into the endometrial cavity in the same way as the intervention group | Failure to achieve a clinical pregnancy after the transfer of at least four good-quality embryos in a minimum of three fresh or frozen cycles to a woman under the age of 40 years | Endometrial thickness; clinical pregnancy rate. Live birth rate |
Huang 2020 China | RCT | 2015.12–2017.7 | Frozen cycle | Administered a 1-ml uterine infusion of recombinant human G-CSF (150 mg, 1 ml, Rubbia, Shandong) through an intrauterine insemination (IUI) catheter | 1. n = 52 intrauterine infusion of saline solution in the same way as the intervention group; 2. n = 59 no treatment | At least two previous implantation failures | Clinical pregnancy rate miscarriage rate; live birth rate |
Scarpellini 2019 Italy | RCT | Not reported | Frozen cycle | Subcutaneous GM-CSF 1.5 mg/kg/daily (60–100) from the day of embryo transfer to the day of b-hcg HCG | Subcutaneous saline solution infusion in the same way as the intervention group | At least 9 good embryos previously transferred, women less than 38 years old | Pregnancy rate |
Arefi 2018 Iran | RCT | 2010.5–2015.10 | Fresh cycle | Recombinant human G-CSF 300 μg (0.5 ml) subcutaneously injected 30 min before blastocyst embryo transfer | Not reported | More than three previous IVF-ET failures | Live birth rate; clinical pregnancy rate |
Tanha 2016 Iran | RCT | 2011.12–2014.1 | Frozen cycle (n = 9) Fresh cycle(n = 91) | G-CSF 300 m0mg/1 m1ml was administered at the day of oocyte puncture or day of progesterone administration of FET cycle | 40 in the saline group;20 in the placebo group | At least three implantation failures with history of transferring at least four good-quality embryos without uterine or thrombophilia factors | Pregnancy rate; implantation rate |
Aleyasin 2016 Iran | RCT | Not reported | Frozen cycle | Subcutaneous 300 μg GCSF before implantation | Not reported | Not reported | Implantation rate; chemical pregnancy rate; clinical pregnancy rate |
Obidniak 2016 Iran | RCT | Not reported | Frozen cycle | 1. Study group No 1: intrauterine perfusion with G-CSF (filgrastim 30 million IU, 1 mL) using insemination catheter 5 days prior to embryo transfer ;2. Study group No 2: G-CSF (filgrastim 30 million IU, 1 ml) was administered subcutaneously once at on the day of embryo transfer | No therapy | At least two cycles of in vitro fertilization in which good-quality embryos (Gardner blastocyst grading system) were transferred in each cycle without achieving a clinical pregnancy | Implantation rate; clinical pregnancy rate |
Maryam 2016 Iran | RCT | 2014.10–2015.2 | fresh cycle | G-CSF 0.5 ml (300 μg/ml) GCSF was infused intrauterine infusion in intervention group | Not reported | Women between 20 and 40 years old with history of at least two implantation failures | Implantation rate; clinical pregnancy rate |
Abedi 2015 Iran | RCT | Not reported | Not reported | Subcutaneous 300 m0mg GCSF before implantation | Not reported | Infertile women with normal endometrial thickness who had 2 implantation failures after IVF cycles | Implantation rate chemical pregnancy rate; clinical pregnancy rate |